logo
  • Home
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
  • Investors
    • Overview
    • News / Events
    • Shareholder Calls/Updates
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News & Media
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact
    • Social Media Community Guidelines

Press Releases

  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
    • 11 DEC 2018

    PharmaCyte Discusses Pancreatic Cancer Clinical Trial with Medpace’s Medical Monitor Dr. Lyon Gleich

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, released an interview with Lyon Gleich, M.D., of Medpace, a global full-service clinical contract research organization (CRO). Dr. Gleich serves as the Medical Monitor and key team

    Read more →
    • Posted in
    • News
    • 04 DEC 2018

    PharmaCyte Biotech Engages cGMP Validation to Assist in Preparation of IND for Pancreatic Cancer Trial

    LAGUNA HILLS, CA, December 4, 2018 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has engaged cGMP Validation L.L.C. (cGMP Validation) to assist in the preparation of the Investigational

    Read more →
    • Posted in
    • News
    • 06 NOV 2018

    PharmaCyte Biotech Selects Medpace as CRO for Its Clinical Trial in Pancreatic Cancer

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has selected Medpace, Inc. as the Contract Research Organization (CRO) to conduct PharmaCyte’s clinical trial in

    Read more →
    • Posted in
    • News
    • 30 OCT 2018

    PharmaCyte Biotech Announces Publication of United States Patent Application for Cancer Therapies

    LAGUNA HILLS, CA, October 30, 2018 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its Patent Application titled “Encapsulated Cells Producing Cytochrome P450 and Methods of Use Thereof,”

    Read more →
    • Posted in
    • News
    • 09 OCT 2018

    PharmaCyte Biotech Announces Publication of PCT Patent Application for Cancer Therapies

    LAGUNA HILLS, CA, October 9, 2018 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its PCT patent application covering a targeted therapy

    Read more →
    • Posted in
    • News
    • 01 OCT 2018

    PharmaCyte Biotech Reports Completion of Crucial FDA-Required Study for Pancreatic Cancer Trial

    LAGUNA HILLS, CA, October 1, 2018 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has successfully determined the modified site and chromosome location of the cytochrome P450-2B1

    Read more →
    • Posted in
    • News
    • 27 SEP 2018

    PharmaCyte Biotech Successfully Completes Comparative Analysis of Methods for Measuring Viability of Encapsulated Cells

    LAGUNA HILLS, CA, September 27, 2018 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has successfully completed a study to determine the best assay method for the accurate determination

    Read more →
    • Posted in
    • News
    • 18 SEP 2018

    PharmaCyte Biotech Successfully Completes Final Pre-Production Run of Pancreatic Cancer Product

    LAGUNA HILLS, CA, September 18, 2018 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its partner, Austrianova, has successfully performed an additional pre-production “engineering

    Read more →
    • Posted in
    • News
    • 23 JUL 2018

    PharmaCyte Biotech Successfully Completes Another Study on the Encapsulated Cells Used in Its Pancreatic Cancer Therapy

    LAGUNA HILLS, CA, July 23, 2018 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has successfully completed a study on the stability after

    Read more →
    • Posted in
    • News
    • 28 JUN 2018

    PharmaCyte Biotech Discusses Importance of Shrinking Pancreatic Cancer Tumors in Latest Q&A Series

    LAGUNA HILLS, CA, June 28, 2018 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the latest in a series of Q&A articles that PharmaCyte conducts with some of the

    Read more →
    • Posted in
    • News
  • 1
  • 2
  • 3